Select Page



Press Releases

Cerespir Incorporated is Pleased with Positive Interim Phase 2 Results for CHF 5074 in Patients with Mild Cognitive Impairment, Presented by Chiesi at the AAIC 2013 Meeting in Boston

Patients with Mild Cognitive Impairment treated with CHF 5074 for up to 90 weeks demonstrated highly statistically significant improvements in verbal memory and executive function CHF 5074 is a first-in-class small molecule microglia modulator, the only compound of... read more